Drug news
EU CHMP recommends extended indication of Ryzodeg (insulin degludec plus insulin aspart) for diabetes mellitus in adults, adolescents and children from the age of 2 years- Novo Nordisk
The EU Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Ryzodeg (insulin degludec plus insulin aspart), from Novo Nordisk. The CHMP adopted a change to the existing indication which now reads: treatment of diabetes mellitus in adults, adolescents and children from the age of 2 years.
Comment: As a combination of two distinct insulin analogues, Ryzodeg is the first combination of a basal insulin with a long duration of action and a well-established mealtime insulin in one pen for people with type 2 diabetes.